The Latest Cardiac and Vascular News
The investigational device evaluated in the trial, previously known as the GORE® VIAFORT Vascular Stent, will now be referred to as the GORE® VIABAHN® FORTEGRA Venous Stent. CAUTION: Investigational device. Limited by United States law to investigational use. LAS VEGAS and FLAGSTAFF, Ariz….
The Velocity System is a next generation percutaneous AVF technology designed to reduce the need for reinterventions to achieve fistula maturation and improve hemodialysis vascular access outcomes while reducing costs. LOS GATOS, Calif., Nov. 6, 2025 /PRNewswire-PRWeb/ — Venova Medical,…
NEW YORK, Nov. 6, 2025 /PRNewswire/ — Koya Medical (“Koya”), an emerging medtech innovator advancing patient-centered solutions in vascular health, has announced its participation in the Stifel 2025 Healthcare Conference on Thursday, November 13, 2025 at 4:00pm EST at the Lotte New York…
LAS VEGAS, Nov. 4, 2025 /PRNewswire/ — The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announced results from four Late-Breaking Clinical Trial sessions at VIVA 2025, held at Wynn…
SOUTH JORDAN, Utah, Nov. 05, 2025 (GLOBE NEWSWIRE) — Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, today announced positive findings from the randomized AVF arm of the WAVE trial. These findings were presented during the Late-Breaking Clinical Trials session on Tuesday, November 4, 2025, at the Vascular Interventional Advances (VIVA)3 conference held in Las Vegas, Nevada.
Microbot Medical® Commences the Limited Market Release of its LIBERTY® Endovascular Robotic System in the U.S.
Data from the POWER PAD II Study presented at VIVA will support FDA 510(k) submission in 2026 WALTHAM, Mass.–(BUSINESS WIRE)–Amplitude Vascular Systems (AVS), a medical device company focused on safely and effectively treating severely calcified arterial disease, presented the results of the first 95 patients treated in the POWER […]
FRANKLIN LAKES, N.J., Nov. 4, 2025 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced full enrollment of the iliac artery patient cohort in its pivotal AGILITY Investigational Device Exemption (IDE) study, a prospective,…
DISRUPT BTK II one-year outcomes data demonstrate the strong safety profile and consistent effectiveness of the Shockwave Peripheral IVL system to help support wound healing and limb preservation LAS VEGAS, November 3, 2025 – Johnson & Johnson MedTech, a global leader in the field of circulatory restoration, today announced the one-year results […]
–The STORM-PE RCT data presented at the VIVA 2025 Conference showed PE patients treated with CAVT in combination with anticoagulation demonstrated significantly greater improvements in thrombus burden reduction, heart rate, oxygen requirement, and functional outcomes compared to those who received only anticoagulation –Results of STORM-PE demonstrating superior efficacy of […]
